Table 1. Studies reporting clinical outcomes in patients with central or peripheral lung lesions treated with stereotactic body radiation therapy.
| Study | Number of patients | Dose | Central or peripheral lesion | Local control | Complications |
|---|---|---|---|---|---|
| Onishi et al.21 | 257 | 1-14 fractions (30-84 Gy) | both | 84% (5 years) BED ≥ 100 Gy | ≥ grade 3: pulmonary complications, in 5.4%; esophageal complications, in 1.0%; dermatitis, in 1.2% |
| Nagata et al.22 | 104 | 4 × 12 Gy | both | 3-year progression-free survival, 69% | grade 3: dyspnea, in 9%; pneumonitis, in 7%; intercostal pain, in 2%; cough, in 1% grade 4: dyspnea, in 1% |
| Baumann et al.23 | 57 | 3 × 15 Gy | peripheral | 92% (3 years) | grade 3: 28% grade 4: 1.7% |
| Senthi et al.24 | 676 | 3-8 fractions (54-60 Gy) | both | 89% (5 years) | - |
| Timmerman et al.18 | 70 | 3 × 20-22 Gy | both | 95% (2 years) | pneumonitis, in 6%; rib fractures, in 3% |
| Brown et al.25 | 59 | 1-5 fractions (15.0-67.5 Gy) | both | disease-free survival, 90% | grade 3: pneumonitis, in 7% |
| Van der Voort et al.26 | 70 | 3 × 12-15 Gy | peripheral | 96% (2 years if dose was = 60 Gy) | late toxicity, in 10% |
BED: biological equivalent dose.